Clinical trial · Interventional
Chemoradiotherapy for Advanced Esophageal Cancer
A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus
NCT02297217CI-TRIAL-00098988PaRCUSrecruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin and Taxol (paclitaxel) | Drug | — | UNRESOLVED |
| External Beam Radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemotherapy with Concurrent Radiation
- description
- Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
- interventionNames
- Drug: Carboplatin and Taxol (paclitaxel)
- Radiation: External Beam Radiation
Primary outcomes (1)
- measure
- Proportion of patients who achieve relief of dysphagia
- timeFrame
- up to day 85
- description
- Will be measured as the proportion of patients who achieve relief of dysphagia, defined as improvement of at least one point on the Mellow Dysphagia Score, measured at Day 57 after the start of radiotherapy, and maintained for at least 28 calendar days (until the Day 85 visit).
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Biopsy proven carcinoma of the esophagus. 2. Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness. 3. Symptomatic patients with Mellow Dysphagia Scores of ≥ 1 i.e. able to eat only some solids. 4. ECOG Performance status ≤ 2. 5. Patients able to begin treatment within 14 days of signing the informed consent form. 6. Patient is at least 18 years old. 7. Hematological function as defined by the following laboratory parameters: * Hemoglobin \> 100g/L * Platelet count \> 100x10E9/L * Absolute neutrophil count \> 1.5x10E9/L 8. Renal function to undergo chemotherapy as defined by the following laboratory parameters: * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x the upper limit of institutional normal (≤ 5 if liver metastases) * Total bilirubin ≤ 1.5x the upper limit of institutional normal * Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula 9. Patients capable of childbearing are using adequate contraception. 10. Written and informed consent of patient. Exclusion Criteria: 1. Previous radiotherapy delivered to the chest. 2. Synchronous active malignancies. 3. Pregnant or lactating patients: women of child bearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of child bearing potential must use effective contraception (defined by the use of two birth control methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF. 4. Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease. 5. Tracheo-esophageal fistula. 6. Esophageal stents in situ. 7. Previous chemotherapy for esophageal cancer 8. Unable to complete surveys in English without aid of interpreter.
References
Publications (0)
Data not yet available
No reference posted for this study.